65,437 trials
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 32 — -0.98; -1.12 percentage of glycosylated haemoglobin — p=0.088
Generalized Anxiety Disorder
Primary: Active Symptoms of Generalized Anxiety Disorder — 13.65; 16.27 units on a scale
Diabetes Mellitus, Type 2 · Obesity
Primary: Success Rate of Biochemical Resolution of Diabetes at 12 Months as Measured by HbA1c ≤ 6%. — 5; 21; 18 participants — p=0.002
Chronic Pain
Primary: Change From Baseline in Pain Intensity Rating at Day 15 — -1.56 Units on a scale
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change in Short Physical Performance Battery (SPPB) Score — 0.6; 0.9 units on a scale — p=0.55
Peripheral Artery Disease
Primary: Composite of Major Adverse Events (MAE) Defined as the Occurrence of In-hospital Myocardial Infarction (MI) or Target Segment Revascularization, Target Limb Loss, or…
Sleep Apnea · Stroke
Primary: Apnea-hypopnea Index — 27; 39 events/hr — p=0.011
Carpometacarpal Osteoarthritis
Primary: The Disabilities of the Arm, Shoulder and Hand Outcome Measure — 12.6 units on a scale
Substance-Related Disorders
Primary: Motivation to Change Substance Use — 88.8; 77.4 units on a scale
Pulmonary Hypertension
Primary: Six Minute Walk Distance (6MWD) — 362.5; 362.5; 367.0; 381.0 meters — p=0.072
Colorectal Cancer
Primary: The Percentage of Patients Experiencing Treatment-related Gastrointestinal Adverse Events ≥ Grade 2 Per National Cancer Institute (NCI) Common Terminology Criteria for…
Kidney Cancer
Primary: Clinical Response as Measured by RECIST — 50 percentage of participants
Postsurgical Pain · Analgesia · Prostatectomy
Primary: The Duration of Abdominal Analgesia From Infiltration Into the TAP — 0.39; 0.44 hours
Pain Control for Intrauterine Device Insertions
Primary: Median Visual Analogue Score Measuring Pain — 12; 8.5; 12; 28 units on a scale
HIV Infections · Pneumococcal Infections
Primary: Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After Dose 2 of 13vPnC to 1 Month After Dose 3 of 13vPnC…